Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This review explains how the mushroom drugs psilocybin and psilocin are broken down in the body. Psilocybin is mainly a pro-drug that enzymes convert into the active compound psilocin. Psilocin is then further changed, and the main substance found in urine is psilocin-O-glucuronide, which matters for clinical and forensic testing.…
This review looked at many studies about classic psychedelics (like psilocybin and LSD), MDMA, ketamine, and plant medicines (like ayahuasca). The authors explain how these drugs can change the brain’s wiring, calm inflammatory processes, and shift key brain chemicals. Those actions may help explain why small clinical trials and animal…
Microdosing means taking a very small, sub‑hallucinogenic amount of a psychedelic drug. Research so far is limited and mixed: some large observational studies report small-to-medium mood gains, but at least one randomized trial found no objective benefit. There is no standard definition of microdosing, potency and legality vary, and long‑term…
In a natural, open-label study at a microdosing event, researchers tested people before and while they expected the effects of a psychedelic truffle microdose. They found better performance on a task that measures convergent thinking and on a task that measures divergent thinking. A short test of fluid intelligence did…
Researchers reviewed studies of drugs that act on serotonin (so-called serotonergic psychedelics) and MDMA. They found that harms and bad reactions are not clearly defined in these studies and are probably reported less often than they actually happen. Some intense or frightening experiences during treatment might help people heal, but…
This review explains the fast-growing problem of so-called "legal highs", which are better called novel psychoactive substances or NPS. Unknown labs keep making slightly different chemicals to avoid bans, and this led to about 80 new substances being spotted in one year. The paper groups these drugs into five main…
This 2018 review looked at animal and human studies of ketamine as a possible treatment for addiction. Early findings are promising: some studies found ketamine helped people stay abstinent from alcohol and heroin and reduced cocaine craving and use. However, the authors say the research is still new, many studies…
This article gives health care professionals a plain overview of psilocybin-assisted psychotherapy. It summarizes how psilocybin and its active form psilocin work in the brain, how the body absorbs and clears them, practical issues for dosing and monitoring, legal and access changes, and safety concerns for medically complex patients. The…
This study used a smartphone app to compare 4,050 people who said they microdose psychedelics with 4,653 people who did not. Psilocybin was the most common microdose substance, and people who microdosed often said they did so for health and wellness reasons. In people who reported past mental health concerns,…
This paper looked across existing studies of psilocybin and found that, when it is given along with psychotherapy or therapy-style support, it looks promising as a treatment for several mental health problems, including cases that did not get better with other treatments. But the authors say the current studies are…
This paper reviews what scientists know about how ketamine and classic serotonergic psychedelics (like psilocybin and LSD) can lift depression quickly. The authors compare how the drugs work in the brain, point out that ketamine has the strongest clinical evidence so far, and say psychedelics show early promise but need…
Researchers followed 953 people who microdosed psilocybin and 180 non-microdosing controls for about 30 days. Microdosers showed small-to-medium improvements in mood and overall mental health at one month compared with controls. These improvements were seen across genders, age groups, and in people with and without prior mental health concerns. The…
